Focused ultrasound (FUS) has emerged as a disruptive technology in the treatment of neurological disorders, enabling the noninvasive interrogation and manipulation of deep brain structures with unprecedented precision. Over the past decade, FUS has evolved from an experimental platform to an established clinical therapy, becoming the most commonly performed surgical treatment for medication-refractory essential tremor. This transformation has demonstrated that targeted interventions within the human brain can be achieved without incisions, implanted hardware, or ionizing radiation. This presentation will review the clinical applications of FUS ablation in movement disorders, with emphasis on essential tremor and Parkinson disease. Current evidence supporting patient selection, target engagement, clinical outcomes, and strategies to improve treatment efficacy and safety will be discussed. The talk will then explore emerging applications of blood-brain barrier opening, including liquid biopsy, biomarker discovery, and targeted delivery of therapeutics to the central nervous system. Beyond ablation and drug delivery, the presentation will highlight the rapidly advancing field of FUS neuromodulation. Preclinical and early clinical investigations suggest that ultrasound can reversibly modulate neural circuits implicated in neuropsychiatric disorders, addiction, and substance use disorders, creating new opportunities for noninvasive circuit-based therapies. Finally, the presentation will examine current technological limitations and future directions for therapeutic ultrasound. Particular attention will be given to advances in histotripsy and related technologies that may further expand the capabilities of incisionless neurosurgery. Together, these developments illustrate how FUS is reshaping the treatment of neurological disease and creating new opportunities at the intersection of engineering, neuroscience, and clinical medicine.